RxDoctor Payments Data

Savanah Querze

Family · Columbia, SCNPI 1235915539

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 69 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$357
  • Novo Nordisk$303
  • Lilly USA, LLC$190
  • Kowa Pharmaceuticals America, Inc.$152
  • Amgen$107
  • Exact Sciences$90
  • plus $387 from 12 others

What the payments were for

  • Food & beverage$1,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,585 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$642
Medicare patients
33
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$25,517
JardianceEmpagliflozin14$20,303
KerendiaFinerenone26$17,787
TrulicityDulaglutide12$12,151
EntrestoSacubitril/Valsartan11$9,863
SymbicortBudesonide/Formoterol Fumarate20$4,542
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,201
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,183
Albuterol Sulfate HfaAlbuterol Sulfate29$950
Atorvastatin Calcium121$930
Gabapentin24$544
Fluticasone Propionate39$504
Omeprazole39$467
Levothyroxine Sodium50$443
Hydroxyzine Hcl20$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$303$25,51725 claims
BayerKerendia$30$17,78726 claims
Lilly USA, LLCTrulicity$190$12,15112 claims
AstraZenecaSymbicort$357$4,54220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →